228 related articles for article (PubMed ID: 21711324)
21. Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells.
Horinaka M; Yoshida T; Kishi A; Akatani K; Yasuda T; Kouhara J; Wakada M; Sakai T
FEBS Lett; 2010 Feb; 584(3):577-82. PubMed ID: 19995562
[TBL] [Abstract][Full Text] [Related]
22. Effect of
Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
Front Immunol; 2019; 10():275. PubMed ID: 30846987
[No Abstract] [Full Text] [Related]
23. Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells.
Oshima K; Yanase N; Ibukiyama C; Yamashina A; Kayagaki N; Yagita H; Mizuguchi J
Cytokine; 2001 May; 14(4):193-201. PubMed ID: 11448118
[TBL] [Abstract][Full Text] [Related]
24. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K
Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus.
Naschberger E; Wenzel J; Kretz CC; Herrmann M; Stürzl M; Kuhn A
Exp Dermatol; 2011 Feb; 20(2):102-6. PubMed ID: 21121962
[TBL] [Abstract][Full Text] [Related]
26. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
Johnsen JI; Pettersen I; Ponthan F; Sveinbjørnsson B; Flaegstad T; Kogner P
Int J Oncol; 2004 Dec; 25(6):1849-57. PubMed ID: 15547726
[TBL] [Abstract][Full Text] [Related]
27. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ
Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827
[TBL] [Abstract][Full Text] [Related]
28. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity.
Wenzel J; Henze S; Brähler S; Bieber T; Tüting T
Exp Dermatol; 2005 Jun; 14(6):454-9. PubMed ID: 15885081
[TBL] [Abstract][Full Text] [Related]
29. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review.
Yu C; Chang C; Zhang J
J Autoimmun; 2013 Mar; 41():34-45. PubMed ID: 23380467
[TBL] [Abstract][Full Text] [Related]
30. C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway.
Secchiero P; Rimondi E; di Iasio MG; Agnoletto C; Melloni E; Volpi I; Zauli G
Clin Cancer Res; 2013 Apr; 19(8):1949-59. PubMed ID: 23468057
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome.
Okuyama S; Komatsuda A; Wakui H; Aiba N; Fujishima N; Iwamoto K; Ohtani H; Sawada K
Nephrol Dial Transplant; 2005 Mar; 20(3):539-44. PubMed ID: 15671071
[TBL] [Abstract][Full Text] [Related]
32. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus.
Abe M; Shimizu A; Yokoyama Y; Takeuchi Y; Ishikawa O
Clin Exp Dermatol; 2008 Nov; 33(6):759-63. PubMed ID: 18713254
[TBL] [Abstract][Full Text] [Related]
33. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus.
Franz B; Fritzsching B; Riehl A; Oberle N; Klemke CD; Sykora J; Quick S; Stumpf C; Hartmann M; Enk A; Ruzicka T; Krammer PH; Suri-Payer E; Kuhn A
Arthritis Rheum; 2007 Jun; 56(6):1910-20. PubMed ID: 17530636
[TBL] [Abstract][Full Text] [Related]
34. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in cytokines in cutaneous and systemic lupus erythematosus.
Mikita N; Ikeda T; Ishiguro M; Furukawa F
J Dermatol; 2011 Sep; 38(9):839-49. PubMed ID: 21767292
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis of cutaneous lupus erythematosus.
Kuhn A; Bijl M
Lupus; 2008 May; 17(5):389-93. PubMed ID: 18490414
[TBL] [Abstract][Full Text] [Related]
37. Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis.
Pablos JL; Santiago B; Galindo M; Carreira PE; Ballestin C; Gomez-Reino JJ
J Pathol; 1999 May; 188(1):63-8. PubMed ID: 10398142
[TBL] [Abstract][Full Text] [Related]
38. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions.
Begue B; Wajant H; Bambou JC; Dubuquoy L; Siegmund D; Beaulieu JF; Canioni D; Berrebi D; Brousse N; Desreumaux P; Schmitz J; Lentze MJ; Goulet O; Cerf-Bensussan N; Ruemmele FM
Gastroenterology; 2006 Jun; 130(7):1962-74. PubMed ID: 16762619
[TBL] [Abstract][Full Text] [Related]
39. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis.
Lood C; Gullstrand B; Truedsson L; Olin AI; Alm GV; Rönnblom L; Sturfelt G; Eloranta ML; Bengtsson AA
Arthritis Rheum; 2009 Oct; 60(10):3081-90. PubMed ID: 19790049
[TBL] [Abstract][Full Text] [Related]
40. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells.
Cederblad B; Blomberg S; Vallin H; Perers A; Alm GV; Rönnblom L
J Autoimmun; 1998 Oct; 11(5):465-70. PubMed ID: 9802930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
